Linda Stevenson with Fisher-Titus Health

Linda Stevenson, CIO of Fisher-Titus, shares why she helped launch the rural health community initiative at CHIME and how it’s creating essential momentum for collaboration. Speaking from VIVE 2025, Linda highlights the unique challenges rural hospitals face—from limited budgets to lean staffing—and the importance of collective action. She emphasizes how vendor education is key: once partners understand rural constraints, they’re more willing to tailor pricing, support, and innovation. Fisher-Titus, despite its size, is now recognized as “Most Wired,” thanks in part to strategic partnerships and creative contracting. But Linda also raises concern over looming Medicaid funding cuts, which could devastate small systems. Her message: unity, innovation, and vendor alignment are crucial for rural healthcare survival in 2025 and beyond.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…